Market Access and Reimbursement for Orphan Drugs & Rare Diseases

Market Access and Reimbursement for Orphan Drugs & Rare Diseases

Overcoming Commercialization, Payer and Regulatory Challenges of Orphan Drugs to Enhance Patient Access

Gold Sponsor: PAREXEL Consulting

Examining Common Market Access Challenges to Review the Current Orphan Drug Environment Tuesday November 16th at 9:45 a.m. Presented by:

Chuck Stevens, Vice President and General Manager, Market Access and Reimbursement, PAREXEL Consulting

Enhance access to rare disease patients through commercialization and patient advocacy groups

Explore the differences between U.S. and Canadian approaches to orphan drug reimbursement

Enhance access to rare disease populations through commercialization and patient advocacy groups

Understand new attempts by the FDA and NORD to improve and update incentives to initiate new trials for Orphan Drugs

Hear from industry leaders on gaining comprehension of patient advocacy, payer and specialty pharmacy groups to access orphan drug populations.

This conference comes at a pivotal time when product patents are coming to an end and companies are looking to replenish their pipelines. Attending this premier conference will give you the opportunity to discuss critical issues, such as the Orphan Drug Act, while benchmarking your market access techniques in order to enhance and grow existing orphan drug portfolios.

Attending this conference will enable you to:

• Discover the incentives of the Orphan Drug Act and other FDA programs for rare diseases.
• Understand the insights, concerns and processes of specialty pharmacies and payers regarding orphan drugs.
• Utilize data and health technology assessment to reduce costs and increase perceived value of orphan drugs

Please join us and take advantage of the PAREXEL discount.

For more information on PAREXEL's Reimbursement and Market Access Services, click here.